Track topics on Twitter Track topics that are important to you
With the development of pharmacogenomics and pharmacogenetics, personalized medicine based on genetic are increasingly required clinically. Incretin-based therapy is currently the most popular diabetes treatment. This study mainly research the correlation of incretin-related gene polymorphism and individual differences in the response of these drugs from the following four aspects.
1. . To study Chinese human gene polymorphism's mutation frequency and allele frequency, by screening Chinese people gene polymorphisms which affecting DPP-4 enzymatic activity.
2. . To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.
3. . By collecting clinical parameters and efficacy indicators to reveal the relationship between Chinese DPP-4 gene and GLP1R gene polymorphism on the clinical manifestations and drug response. This study will be improved based on actual experimental research methods, and design intervening measures for Chinese people, to explore the dose-effect relationship of DPP-4 and GLP1R gene polymorphism in the treatment of diabetes in Chinese population.
4. . Incretins is a new generation hypoglycemic agent. By studying gene polymorphism and drug response, to research how to plan treatment for clinical diabetes with DPP-4 and GLP1R gene polymorphism. Provide the basis for individualized treatment of these drugs.
Sichuan provincial people's hospital
Sichuan Provincial People's Hospital
Published on BioPortfolio: 2017-04-12T04:08:21-0400
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin...
A clinical study determines the safety and efficacy of sitagliptin (MK0431) in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic...
Diabetes mellitus is a progressive disease with cardiovascular complications. This study evaluated the effects of liraglutide, a glucagon-like peptide-1 analog, and the dipeptidyl peptidase 4 inhibito...
To investigate the effect of anti-diabetic agents on nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes (T2DM), 75 patients with T2DM and NAFLD under inadequate glycemic control...
Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfo...
Many adipocytokines correlate with obesity and insulin resistance(IR). we examined the effects of metformin, sitagliptin, and liraglutide in diabetic rats. Group 1: control normal (CN) received oral s...
Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes:...
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
An analog of GLUCAGON-LIKE PEPTIDE 1 and agonist of the GLUCAGON-LIKE PEPTIDE 1 RECEPTOR that is used as a HYPOGLYCEMIC AGENT and supplemental therapy in the treatment of DIABETES MELLITUS by patients who do not respond to METFORMIN.
A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...